Full Text View
Tabular View
No Study Results Posted
Related Studies
Feasibility Study of a Chronic Retinal Stimulator in Retinitis Pigmentosa
This study is ongoing, but not recruiting participants.
First Received: January 17, 2006   Last Updated: January 8, 2007   History of Changes
Sponsored by: Second Sight Medical Products
Information provided by: Second Sight Medical Products
ClinicalTrials.gov Identifier: NCT00279500
  Purpose

The objective of this study is to evaluate the safety and efficacy of the retinal stimulation system by evaluating the data after chronic implantation.


Condition Intervention Phase
Retinitis Pigmentosa
Device: Argus 16 Retinal Stimulation System
Phase I
Phase II

Genetics Home Reference related topics: Lenz microphthalmia syndrome oculofaciocardiodental syndrome Peters plus syndrome X-linked juvenile retinoschisis
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: Chronic Retinal Electrodes to Provide Electrical Stimulation of the Retina to Elicit Visual Percepts in Blind Subjects

Further study details as provided by Second Sight Medical Products:

Primary Outcome Measures:
  • Medical and surgical risk as a result of device usage.
  • Subject risk as a result of chronic electrical stimulation.
  • Ability to resolve multiple percepts and patterns.
  • Optimize effectiveness of stimulus parameters.

Estimated Enrollment: 8
Study Start Date: February 2002
Estimated Study Completion Date: December 2007
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed history of retinal degenerative disease in the worse seeing eye with remaining vision no better than light perception. The fellow eye can have any visual acuity but must have better vision than the eye that will have the surgery.
  • History of former useful form vision in worse-seeing eye
  • Acceptable ability to describe visual percepts
  • Age eighteen (18) or older

Exclusion Criteria:

  • History of glaucoma
  • Optic neuropathy or other confirmed damage to optic nerve or visual cortical damage
  • Presence of communicable disease/infection
  • Pregnancy
  • History of claustrophobia
  • Inconsistent flash detection thresholds
  • Any other diseases that can effect the function of the retina
  • Subjects with a Beck Depression Inventory Interpretation score of >30 and subsequent diagnosis of depression by a psychiatrist.
  • Corneal degeneration
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00279500

Locations
United States, California
Doheny Eye Institute
Los Angeles, California, United States, 90033
Sponsors and Collaborators
Second Sight Medical Products
Investigators
Principal Investigator: Mark Humayun, MD PhD Doheny Eye Institute
  More Information

No publications provided by Second Sight Medical Products

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):
Study ID Numbers: CP0002
Study First Received: January 17, 2006
Last Updated: January 8, 2007
ClinicalTrials.gov Identifier: NCT00279500     History of Changes
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Pigmentary Retinopathy
Cone Rod Dystrophy
Genetic Diseases, Inborn
Eye Diseases
Retinitis Pigmentosa
Retinitis
Retinal Degeneration
Eye Diseases, Hereditary
Retinal Diseases

Additional relevant MeSH terms:
Genetic Diseases, Inborn
Eye Diseases
Retinitis Pigmentosa
Retinitis
Retinal Degeneration
Eye Diseases, Hereditary
Retinal Diseases

ClinicalTrials.gov processed this record on May 07, 2009